2023
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
Bergaggio E, Tai W, Aroldi A, Mecca C, Landoni E, Nüesch M, Mota I, Metovic J, Molinaro L, Ma L, Alvarado D, Ambrogio C, Voena C, Blasco R, Li T, Klein D, Irvine D, Papotti M, Savoldo B, Dotti G, Chiarle R. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 2023, 41: 2100-2116.e10. PMID: 38039964, PMCID: PMC10793157, DOI: 10.1016/j.ccell.2023.11.004.Peer-Reviewed Original ResearchConceptsALK inhibitorsALK expressionChimeric antigen receptor TBest tumor antigensPromising clinical activityExpression of ALKMost normal tissuesHematologic malignanciesClinical activityMost neuroblastomasAnaplastic lymphoma kinase (ALK) receptorTherapeutic successTumor antigensPotent efficacySolid tumorsTherapeutic efficacyNeuroblastomaTumor growthOncogenic driversNeuroblastoma cellsNormal tissuesALKKinase receptorsMonotherapyInhibitors
2016
Novel Inhibitors of Toxin HipA Reduce Multidrug Tolerant Persisters
Li T, Yin N, Liu H, Pei J, Lai L. Novel Inhibitors of Toxin HipA Reduce Multidrug Tolerant Persisters. ACS Medicinal Chemistry Letters 2016, 7: 449-453. PMID: 27190591, PMCID: PMC4867474, DOI: 10.1021/acsmedchemlett.5b00420.Peer-Reviewed Original ResearchLife-threatening infectious diseaseDrug-tolerant bacteriaAntibiotic therapyNovel inhibitorsInhibition of toxinMultidrug-tolerant persistersFirst toxinInfectious diseasesEscherichia coli persistenceBacterial persistencePotent oneInhibitorsTolerant persistersPersister fractionToxinToxin-antitoxin modulesTherapyPersistersDisease